Current Report Filing (8-k)
August 03 2020 - 8:49AM
Edgar (US Regulatory)
0000203527
false
0000203527
2020-08-02
2020-08-02
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
___________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported)
|
August 3, 2020 (August 2, 2020)
|
VARIAN MEDICAL SYSTEMS, INC.
|
(Exact Name of Registrant as Specified in its Charter)
|
Delaware
|
1-7598
|
94-2359345
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission File
Number)
|
(IRS Employer
Identification No.)
|
3100 Hansen Way, Palo Alto, CA
|
94304-1030
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant's telephone number, including area code
|
(650) 493-4000
|
Not Applicable
|
(Former Name or Former Address, if Changed Since Last Report)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2 below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company indicate by check mark if the
registrant has elected not to use the extended transaction period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
Title of each class:
|
Trading Symbol(s)
|
Name of each exchange on which registered:
|
Common Stock, $1 par value
|
VAR
|
New York Stock Exchange
|
Item 2.02. Results
of Operations and Financial Conditions.
On August 2, 2020, Varian Medical
Systems, Inc. (the “Company”) issued a press release announcing its preliminary results of operations for the
three months ended July 3, 2020. A copy of the press release is attached as Exhibit 99.1. A slide presentation, which
includes supplemental information relating to the Company, is attached as Exhibit 99.2. The exhibits will be posted on the
Company's website at www.varian.com under the "Investors" section.
The information furnished under Item 2.02
of this Current Report on Form 8-K, including the exhibits, shall not be deemed "filed" for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference
into the Company’s filings with the SEC under the Securities Act of 1933, as amended, or the Exchange Act, except as shall
be expressly set forth by specific reference in such a filing.
Item 9.01. Financial
Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Varian Medical Systems, Inc.
|
|
|
|
|
|
By:
|
/s/ J. Michael Bruff
|
|
Name:
|
J. Michael Bruff
|
|
Title:
|
Senior Vice President and Chief Financial Officer
|
Dated: August 3, 2020
Varian Medical System (NYSE:VAR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Varian Medical System (NYSE:VAR)
Historical Stock Chart
From Apr 2023 to Apr 2024